Motzer RJ, Russo P, Haas N, et al. - Researchers designed a randomized, double-blind, placebo-controlled phase 3 study (PROTECT) to assess adjuvant pazopanib in patients with locally advanced renal cell carcinoma (RCC) at high risk of relapse after nephrectomy (pazopanib, n = 769; placebo, n = 769). No difference in disease-free survival between pazopanib 600 mg and placebo was seen in the results of the primary analysis, so here researchers reported the final overall survival (OS) analysis. There was no variation in disease-free survival between pazopanib 600 mg and placebo. For patients with locally advanced RCC at high risk of relapse following nephrectomy who received adjuvant therapy with pazopanib or placebo, overall survival was comparable. The results support that pazopanib should not be recommended as adjuvant therapy afterresection of locally advanced RCC.